Lead Product(s) : CT1812
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Cognition Says Oral CT1812 Reduced Lesion Growth in GA Phase 2 Trial
Details : CT1812 (zervimesine) is a sigma-2 receptor binder, being investigated as a potential oral treatment for adults with geographic atrophy (GA) secondary to dry age-related macular degeneration (dry AMD).
Product Name : CT1812
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 08, 2025
Lead Product(s) : CT1812
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable